白介素-6、血管内皮生长因子、D-二聚体对CSDH的影响

目的探讨血肿局部炎症、假膜新血管生成、局部纤溶状况及其在CSDH发生、发展中的作用。进而探讨CSDH的发病机制，并为CSDH的治疗及预防复发提供理论依据。方法以78例CSDH患者作为病例组，20例健康人作为正常对照组。采用ELISA法测定患者血清及血肿液中VEGF及IL-6的含量。比较患者末梢静脉血及血肿液中四种因子的含量变化并与正常对照组比较。结果病例组血肿液FDP、d-dimer检测均为阳性，血液为阴性；正常对照组血液FDP、d-dimer检测均为阴性；病例组血清VEGF含量与正常对照组比较差异无统计学意义。血肿液中VEGF浓度高于血清中。病例组血清IL-6浓度与正常对照组差异无统计学意义，血肿液中IL-6浓度高于血清中。CSDH患者血肿液VEGF、IL-6水平没有相关性。结论CSDH患者血肿液局部纤溶亢进，局部VEGF分泌旺盛，新血管生成活跃，局部炎症活跃，可导致CSDH不断扩大而参与CSDH发病机制。抗炎治疗、抑制VEGF的生理作用、有选择的对病人施行促凝治疗，可成为部分CSDH病人保守治疗及预防复发的有效手段。     

Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?

Bone scintigraphy plays a major role in the diagnosis of bone metastases. The clinical utility of new biochemical markers of bone metabolism has recently been investigated in various bone diseases. This study evaluated the role of some bone metabolism markers in comparison with bone scan in the follow-up of breast cancer patients. We studied 149 patients with breast cancer, 33 (22%) of whom had bone metastases. IRMAs were used for the evaluation of blood levels of osteocalcin, bone alkaline phosphatase (BAP), the C-terminal propeptide of type I procollagen and the C-terminal cross-linked telopeptide of type I collagen (ICTP). Multivariate regression analysis showed that menopausal status (P=0.007) and metastatic bone lesions (P=0.001) affected bone marker levels. When considering post-menopausal women, the only subset in which bone metabolism marker behaviour could be reliably investigated, we found a high degree of overlap in marker distribution for scan-positive and scan-negative patients. Discrimination between scan-negative and scan-positive patients based on the above markers, taken singly or jointly, was assessed by means of logistic discriminant analysis. The best discrimination was achieved with BAP, closely followed by ICTP. BAP and ICTP together gave a slight improvement over the use of the two markers separately. However, even in this case the degree of discrimination was poor and its clinical utility was limited. In fact, to achieve a specificity of 95%, the sensitivity of the test was about 20%; conversely, with a sensitivity of 95%, the specificity was below 10%. In conclusion, based on our findings, we believe that blood levels of the investigated markers cannot replace bone scintigraphy in the follow-up of breast cancer patients for the early detection of bone metastases. Received 14 April and in revised form 5 July 1997     

急性白血病血浆及脑脊液D-dimer测定的临床意义

目的 探讨D-dimer(DD)在中枢神经系统白血病及急性白血病诊断、治疗中的价值。方法 采用ELISA法检测54例急性白血病(AL)患者脑脊液(CSF)DD水平，并对其中伴中枢神经系统白血病(CNSL)22例进行动态观察，同时检测7例上呼吸道感染，9例贫血患者CSFDD水平作对照。结果 CNSL组明显高于非中枢神经系统白血病(NCNSL)组及对照组。22例CNSL患者鞘内注射化疗药后。20例达完全缓解(CR)，DD值明显下降。2例无效者，CSFDD维持于较高水平。1例缓解后再次复发者，CSFDD含量再次升高。1例患者在CSF常规、生化确诊CNSL之前，CSF D-dirner已有改变。CNSL组CSFDD含量与CSF压力、白细胞数、蛋白含量均无明显相关关系。结论 DD对CNSL早期诊断、疗效观察、预后估计很有价值。     

祛瘀消斑胶囊治疗不稳定型心绞痛及对其血浆Fib、DD的影响

目的　观察祛瘀消斑胶囊治疗不稳定型心绞痛及对其血浆Fib和DD水平的影响。方法　对 4 0例不稳定型心绞痛患者随机分为常规西药加祛瘀消斑胶囊治疗组 (治疗组 )和常规西药治疗组 (对照组 ) ,治疗组与对照组各 2 0例。采用相应药物治疗 4周后 ,观察 2组患者的临床疗效、心电图改善及硝酸酯类药物的停减率 ,以及血浆Fib、DD水平变化 ,并进行比较分析。结果　治疗组可显著改善心绞痛症状 ,与对照组比较有显著性差异 (P <0 .0 5 ) ,2组患者心电图改善情况及硝酸酯类药物减停率无显著性差异 (P >0 .0 5 )。治疗组降低Fib、DD水平 ,与对照组比较有显著性差异 (P <0 .0 5 )。 2组均未出现明显不良反应。结论　祛瘀消斑胶囊可显著降低不稳定型心绞痛患者Fib、DD水平 ,联合西药治疗不稳定型心绞痛 ,疗效优于单用西药 ,且安全可靠。     

Influence of heparin on fibrinogen and D-dimer plasma levels in acute myocardial infarction treated with streptokinase

The purpose of this study was to investigate whether, to whatextent, and through which mechanisms intravenous heparin, administeredbefore and after streptokinase, affects the plasma levels ofD-dimer and fibrinogen in myocardial infarction. Data concerningmortality and incidence of coronary recanalization in patientsreceiving heparin and thrombolytic therapy after acute myocardialinfarction are controversial; furthermore, the mechanisms throughwhich heparin acts in combination with thrombolytic therapyare unclear. Thirty-eight patients with acute myocardial infarctiontreated with streptokinase were considered. Nineteen of themreceived, immediately before the beginning of thrombolytic treatment,a bolus of heparin (100 U. kg¹ intravenously) and, 2 h later,intravenous heparin in doses raising the partial thromboplastintime to 2-2.5 times the normal value (Group 1); the remaining19 did not receive anticoagulant treatment (Group 2). Multipledeterminations of plasma D-dimer and fibrinogen levels wereobtained in all patients before, and in the seven days followingthrombolytic treatment. Six hours after streptokinase, fibrinogendecreased from 304 ± 34 to 61 ± 34 mg. dt¹ inGroup 1 and from 312 ± 29 to 38 ±21 mg. dt¹ inGroup 2 (P<002 versus Group 1). The same difference betweengroups persisted at the 12th and at the 18th hour. D-dimer values,from 0-5 ± 01 \ig. dl¹ in Group 1 and 04 ±01 fig.dt¹ in Group 2, increased at the 1st hour to 37.2 ± 36.5fig. dt¹ and 52.2 ± 39.8 µg. dl¹, respectively.A peak value was reached in both groups at the 6th hour, whichwas followed by a slow decrease. A significant difference betweenthe two groups (P<0.05) was observed at the 1st, 2nd, 4thand 6th hour. An inverse correlation between maximal changesof fibrinogen and of D-dimer was found in both groups (r= 0.89,P<0.001 in Group 1; r=-0.81, P<0.001 in Group 2). The relationship between D-dimer and fibrinogen variations afterstreptokinase and changes induced by heparin, support the hypothesisthat the decrease of fibrinogen, following thrombolysis, isnot only the consequence of its direct degradation, but alsothe result of its transformation by streptokinase into fibrin,fibrin cross-linked (with facilitation of thrombogenic condition)and then into the stable catabolite, D-dimer. These data confirma thrombogenic effect of streptokinase therapy; this tendencycan be limited by prompt use of high doses of heparin.     

In vivo measurements of fibrin formation and degradation in nephrotic patients

Summary Intraglomerular fibrin deposition has been implicated as an important pathogenetic mechanism in patients with glomerular diseases and the nephrotic syndrome. To investigate fibrin formation and degradation in nephrosis, we measured fibrinopeptide A by radio-immunoassay and D-dimer by enzyme-linked immunosorbent assay in the plasma of 30 consecutive adult patients with the nephrotic syndrome; in 10 the serum creatinine was more than 2 mg/dl. Both fibrinopeptide A and D-dimer were abnormally elevated in the majority of nephrotics (P<0.001 vs. healthy controls), providing evidence of increased fibrin generation and lysis “in vivo.” A positive correlation was found between fibrinopeptide A and D-dimer (correlation coefficient 0.64,P<0.001), suggesting a close relationship between fibrin formation and degradation. Calcium heparin, administered to 12 nephrotics, caused a marked decrease in plasma fibrinopeptide A, due to a reduction of in vivo thrombin activity. As enhanced thrombin activity can favor fibrin deposition within the renal parenchyma, as well as vascular complications, it is reasonable to assume that an antithrombotic treatment aimed at controlling thrombin generation may ameliorate the natural history of nephrosis.     

冠心病患者血浆D-二聚体水平测定及其临床意义

目的:探讨D-二聚体(D-dimer)含量与冠心病(CHD)临床类型、病变程度的关系,以了解D-二聚体在冠心痛诊断和预后判断方面的临床意义。方法:用Liatest法检测急性心肌梗死(AMI)21例、不稳定型心绞痛(UA)27例、稳定型心绞痛(SA)22例、健康者30例的血浆D-二聚体水平。结果:D-二聚体阳性发生率与含量在UA和AMI组明显高于SA组和对照组(P<0.01),且AMI组的D-二聚体含量明显高于UA组(P<0.01),SA组的D-二聚体无明显增高。结论:冠心病患者存在凝血和纤溶功能异常,且异常程度与病情严重程度密切相关。     

不同孕期阶段孕妇凝血四项及FDP和D-二聚体的变化及临床意义

目的:研究不同孕期阶段(早、中、晚)孕妇凝血四项、血浆纤维蛋白(原)降解产物[plasma fibrin/fibrinogen degradation products, FDP]、D-二聚体的变化及临床意义,为临床诊疗提供理论支持。方法:回顾性分析2021年1月至2021年12月200例孕妇就诊资料中的凝血四项,纤维蛋白原(fibrinogen, FIB)、凝血酶原时间(prothrombin time, PT)、凝血酶时间(thrombin time, TT)、活化部分凝血活酶时间(activated partial thromboplastin time, APTT)。并对FDP与D-二聚体的检测结果进行统计分析,比较孕早期、中期、晚期三个阶段凝血四项、FDP和D-二聚体水平的变化。结果:孕早期、孕中期与孕晚期PT水平比较,差异有统计学意义(P<0.05);孕早期、孕中期与孕晚期三个阶段的TT相比,差异无统计学意义(P>0.05);孕早期的APTT明显长于中期、晚期孕妇,差异有统计学意义(P<0.05);孕早期、中期、晚期孕妇,随着孕周的增加,FIB水平逐渐升高...     

超声心动图和下肢静脉超声联合血浆D-二聚体对孕产妇肺栓塞的临床诊断价值

目的分析和评价超声心动图和下肢静脉超声联合血浆D-二聚体对孕产妇肺栓塞（pulmonary thromboembolism, PE）的临床诊断和预测价值。方法回顾性收集2019年5月—2021年5月同济大学附属第一妇婴保健院收治120例临床疑诊PE的孕产妇临床资料,按照肺动脉断层血管造影（computed tomographic pulmonary angiographic, CTPA）的结果分为阴性组和阳性组,比较和评价超声心动图、下肢静脉超声、血浆D-二聚体单独及联合诊断孕产妇PE的临床诊断和预测效能。结果临床特征比较： 两组间年龄、孕次、产次、受孕方式、受孕胎数、终止妊娠方式、是否早产、既往妇产科手术史、既往外科手术史、是否合并高血压、糖尿病、肥胖及BNP等指标比较差异均无统计学意义（均P>0.05）。两组间仅血浆D-二聚体比较差异有统计学意义（t=-3.598,P＜0.001）。超声心动图、下肢静脉超声和血浆D-二聚体升高单独及联合诊断孕产妇PE的灵敏度分别为45.00%、53.33%、95.00%和85.00%,特异度分别为83.33%、91.67%、21.67%和81.67%,阳性预测值分别为72.97%、86.49%、54.81%和82.26%,阴性预测值分别为60.24%、66.27%、81.25%和84.48%。与单独诊断相比较,联合诊断显著提高灵敏度（χ2=49.669,P＜0.001）、特异度（χ2=88.413,P＜0.001）、阳性预测值（χ2=20.629,P＜0.001）和阴性预测值（χ2=11.169,P=0.01）。多因素Logistic回归分析提示超声心动图阳性（OR=18.266,P＜0.001）、下肢静脉血栓（OR=45.482,P＜0.001）及D-二聚体升高（OR=6.595,P=0.019）与孕产妇PE发生显著相关,ROC曲线分析显示单独及联合诊断的曲线下面积（AUC）分别为0.642、0.725、0.583和0.833。结论超声心动图和下肢静脉超声联合血浆D-二聚体对孕产妇PE具有良好的诊断和预测价值,为临床早期预防、诊断和治疗提供可靠依据。     

急性脑梗死患者血清CTRP-3、D-二聚体、sTREM2水平及相关临床特征与溶栓后出血性转化的关系

目的 探讨急性脑梗死患者血清补体C1q/肿瘤坏死因子相关蛋白3（CTRP-3）、D-二聚体、可溶性髓样细胞触发受体2（sTREM2）水平及相关临床特征与溶栓后出血性转化（HT）的关系。方法 回顾性分析2018年9月—2022年9月在青海省人民医院接受溶栓治疗的120例急性脑梗死患者的临床资料,根据患者溶栓后是否发生HT分为HT组（30例）、非HT组（90例）。比较两组患者的临床资料及血清CTRP-3、D-二聚体、sTREM2水平。采用多因素逐步Logistic回归分析急性脑梗死患者溶栓后发生HT的危险因素;绘制受试者工作特征（ROC）曲线,分析急性脑梗死患者溶栓后HT预测模型预测HT发生的价值。结果 HT组心房颤动（以下简称房颤）、大面积脑梗死、入院NIHSS评分≥ 15分占比高于非HT组（P <0.05）,血清CTRP-3水平低于非HT组（P <0.05）,D-二聚体、sTREM2水平高于非HT组（P <0.05）。血清CTRP-3、D-二聚体、sTREM2水平预测急性脑梗死患者溶栓后发生HT的敏感性分别为66.7%（95% CI：0.598,0.756）、70.0%（95% CI：0.607,0.812）、80.0%（95% CI：0.714,0.889）,特异性分别为73.3%（95% CI：0.636,0.821）、86.7%（95% CI：0.778,0.923）、86.7%（95% CI：0.747,0.942）。多因素Logistic逐步回归分析结果显示,房颤［O^R=1.237（95% CI：1.103,1.387）］、大面积脑梗死［O^R=2.338（95% CI：1.292,4.231）］、入院NIHSS评分≥ 15分［O^R=2.087（95% CI：1.231,3.538）］、CTRP-3 ≤ 269.265 μg/L ［O^R=3.006（95% CI：1.508,5.992）］、D-二聚体≥ 2.625 mg/L ［O^R=2.649（95% CI：1.374,5.107）］、sTREM2 ≥ 314.675 ng/L ［O^R=2.328（95% CI：1.411,3.841）］是急性脑梗死患者溶栓后发生HT的危险因素（P <0.05）。根据多因素Logistic逐步回归分析结果建立急性脑梗死患者溶栓后HT预测模型,Logit（P） = -33.887 + 0.213×房颤+ 0.849×大面积脑梗死+0.736×入院NIHSS评分+ 1.101×CTRP-3 + 0.974×D-二聚体+ 0.845×sTREM2;ROC曲线分析结果表明,预测模型预测HT发生的敏感性为93.3%（95% CI：0.841,0.991）,特异性为87.8%（95% CI：0.808,0.976）。结论 血清CTRP-3、D-二聚体、sTREM2水平与急性脑梗死患者溶栓后HT有关,预测价值较高,且急性脑梗死患者溶栓后HT预测模型预测HT优于各项指标单独预测。